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Abstract
The molecular mechanisms of Idiopathic Pulmonary Fibrosis (IPF) remain elusive. Transforming
Growth Factor beta 1(TGF-β1) is a key effector cytokine in the development of lung fibrosis. We
used microarray and computational biology strategies to identify genes whose expression is
significantly altered in alveolar epithelial cells (A549) in response to TGF-β1, IL-4 and IL-13 and
Epstein Barr virus.
A549 cells were exposed to 10 ng/ml TGF-β1, IL-4 and IL-13 at serial time points. Total RNA was
used for hybridisation to Affymetrix Human Genome U133A microarrays. Each in vitro time-point
was studied in duplicate and an average RMA value computed. Expression data for each time point
was compared to control and a signal log ratio of 0.6 or greater taken to identify significant
differential regulation. Using normalised RMA values and unsupervised Average Linkage
Hierarchical Cluster Analysis, a list of 312 extracellular matrix (ECM) proteins or modulators of
matrix turnover was curated via Onto-Compare and Gene-Ontology (GO) databases for baited
cluster analysis of ECM associated genes.
Interrogation of the dataset using ontological classification focused cluster analysis revealed
coordinate differential expression of a large cohort of extracellular matrix associated genes. Of this
grouping members of the ADAM (A disintegrin and Metalloproteinase domain containing) family of
genes were differentially expressed. ADAM gene expression was also identified in EBV infected
A549 cells as well as IL-13 and IL-4 stimulated cells. We probed pathologenomic activities
(activation and functional activity) of ADAM19 and ADAMTS9 using siRNA and collagen assays.
Knockdown of these genes resulted in diminished production of collagen in A549 cells exposed to
TGF-β1, suggesting a potential role for these molecules in ECM accumulation in IPF.
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive and
lethal pulmonary fibrotic lung disease. It is the most com-
mon form of the idiopathic interstitial pneumonias and is
unresponsive to treatment resulting in a median survival
from diagnosis of 2.9 years [1]. Although the pathogenesis
of IPF remains elusive, a number of conditions and risk
factors are associated with the disease, including cigarette
smoking, several viral proteins, and genetic predisposi-
tion to IPF [2].
During both lung development and fibrogenesis, mesen-
chymal signaling alters alveolar epithelial cell phenotype
and regulates pneumocyte differentiation [3,4]. Effective
cell function in both the epithelium and the mesenchyme
is dependent on signals originating in both compart-
ments, acting in a complimentary axis. In disease the
unchecked signaling emanating from these compartments
establishes persistent fibroblast migration and extracellu-
lar matrix deposition with resultant pulmonary fibro-
sis[5].
Injured alveolar epithelail cells release a number of profi-
brotic cytokines including transforming growth factors-
beta-1, platelet derived growth factor tumour necrosis fac-
tor-alpha and interleukin-1 [6]. As a result of these medi-
ators being released there a chemoattraction gradient for
fibroblasts toward these areas of lung, with subsequent
phenotypic differentiation.
TGF-β1 is a prominent mediator in normal wound repair
without the development of fibrosis[8]. Excess produc-
tion of latent TGF-β1 and active TGF-β1 has been associ-
ated with the development of temporary inflammation,
however, only TGF-β1 overexpression results in fibroblast
migration and proliferation with increased deposition of
extracellular matrix. This suggests that inflammation in
IPF is not crucial for pathogenesis but may instead be an
associated phenomenon [9].
Targeted overexpression of TGF-β1 is associated with aug-
mented fibrosis, while antagonism of the growth factor
results in abrogation o the fibrotic process. TGF-β1 knock-
out mice die prematurely due to developmental retarda-
tion and progressive inflammation[10]; however,
treatment with TGF-β1 specific antagonists in mice did
not result in a significant disturbance of the immune sys-
tem[11]. TGF-β1 has been shown to augment epithelial
cell apoptosis and inhibition of this process has been
shown to reduce fibrosis in animal models[12,13]. In
other studies instillation of apoptotic cells into inflamed
lungs has accelerated healing in a TGF-β1 dependent
manner[14].
TGF-β1 is consistently associated with progressive fibrosis
with increased expression being associated with a variety
of fibrotic lung disease [15-17]. Adenovirus-mediated
gene transfer of TGF-β1 resulted in severe fibrosis in ani-
mal models[15]; while αVβ6 integrin (a TGF-β1 activator)
knockout mice developed lung inflammation but not
fibrosis in response to bleomycin[18]. TGF-β1 displays a
pivotal role in the development of a fibrotic process in
animal models, however the reasons surrounding its over-
expression and the predilection towards a fibrotic pheno-
type in this setting remains unexplained.
Interleukin (IL)-13, a Th2 cytokine, has been shown to be
increased in IPF [19], while the lungs of mice injured with
bleomycin display increased IL-13 and its receptor IL-
13Ralpha2 [20]. The vehicle for fibrosis in response to IL-
13 is activated TGF-β1 [21]. In asthmatic individuals the
overexpression of IL-13 is associated with subepithelial
fibrosis which has obvious implications for the develop-
ment of idiopathic fibrosis [22]. IL-4 is also increased in
the lungs of IPF patients and in bleomycin murine models
[23]. The role for IL-4 in IPF may be two fold, limiting T-
cell migration and stimulating fibrosis. IL-4 transforms
fibroblasts into myofibroblasts inferring a role in the
fibrotic process [24]. Through the release of TGF-β2 IL-4
initiates the release of matrix proteins by myofibroblasts
while inhibition of its receptor in bleomycin-injured mice
attenuates the fibrotic response [20,22].
Epstein-Barr virus (EBV) is a ubiquitous human herpesvi-
rus associated with various diseases including infectious
mononucleosis, Burkitt's lymphoma and Hodgkin's dis-
ease. A link between EBV and IPF has been suggested since
Vergnon and colleagues demonstrated an elevation in the
IgA levels against viral capsid antigen in IPF patients [25].
EBV usually infects the upper respiratory tract but has also
been shown to infect and replicate in the lower respiratory
tract. Immunohistochemical studies suggest that this rep-
lication occurs in the type II alveolar epithelial cells [26].
Further evidence for EBV involvement in IPF comes from
the observation of a poorer prognosis in these patients
when associated with EBV latent membrane protein 1
(LMP1) in epithelial cells [27]. LMP1 is an EBV associated
protein expressed on the surface of EBV Infected cells in
the latent and replicating phase [28]. Aberrant DNA
found in lung tissue and serum of IPF patients suggested
a mechanism by which a persistent virus can change from
a latent to a productive phase via recombinatorial events
[29].
In this study we explore the multifactorial nature of epi-
thelial cell injury in pulmonary fibrosis in response to
potential fibrogenic stimuli.Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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Methods
Cell culture and EBV Infection in vitro
Human alveolar epithelial cells (A549) were obtained
from European Collection of Cell Cultures (Salisbury,
United Kingdom) and grown in vitro in Hams F12 (Life
Technologies, Paisley, Scotland) supplemented with 10%
fetal calf serum, 146 mg/L L-glutamine, 1% penicillin and
1% streptomycin. For stimulation experiments, cells were
serum starved overnight before exposure to 10 ng/ml TGF-
β1, IL-4 or IL-13 (Sigma) for the indicated time points,
control samples were maintained in serum free condi-
tions.
To effect virus infection, A549 cells were co-cultured with
Akata cells (an Epstein-Barr virus-negative cell line
infected with recombinant EBV carrying the neomycin
resistance gene) [30]. The Akata cell line was maintained
in RPMI 1640 (Life Technologies, Paisley, Scotland) sup-
plemented with 10% FBS, 2 mM L-glutamine, 100 U/ml
Penicillin, 100 µg/ml streptomycin and 700 µg/ml G418.
The viral lytic cycle was induced in the Akata cells by add-
ing goat anti-human serum Immunoglobulin G (Sigma)
at 100 µg/ml. After four hours the Akata cells were added
to the A549 wells at a concentration of 5 × 105/ml. After
two days incubation half the medium was replaced with
medium containing 5% FCS. Following a further 4 days
incubation the media containing the Akata cells was
removed, pelleted down and resuspended in M5 media
(Calcium free DMEM supplemented with 5% Horse
Serum, 2 mM glutamine, cortisol, 2 ng/ml EGF, 10 mg/ml
Insulin, 100 ng/ml cholera toxin, 100 U/ml Penicillin and
100 µg/ml streptomycin). 2 mls of this cell suspension
was then placed onto the wells and left to incubate for 2
days. The wells were washed with PBS and the media
replaced with fresh medium containing 10% FCS. Follow-
ing incubation for 24 hours 700 ng/ml G418 (Sigma) was
added to select for EBV-infected A549 cells.
Western blot analysis
Latent infection of the A549 cells with EBV was confirmed
by the detection of latent membrane protein 1 (LMP1) by
Western blot. After removal of EBV/A549 cells from flasks
protein lysates were prepared by boiling for 10 minutes in
2% SDS, 100 mM NaCl, 0.01 M Tris-HCl, 5% β-Mercap-
toethanol, 1 mM EDTA, 100 µg of phenylmethylsulfonyl
fluoride/ml, and 2 µg of leupeptin/ml. The product was
then sonicated on ice and clarified at room temperature
by centrifugation at 12,000 rpm for 10 min. Protein frac-
tionated by discontinuous SDS-5–10% polyacrylamide
gel electrophoresis and blotted onto a nitrocellulose filter.
Anti-LMP1 CS1-4 antibody (University of Wales, Cardiff)
cocktail diluted to 1:100 in Blotto (5% skim milk and
0.1% Tween 20 in Tris-buffered saline) was used to probe
the filters at 4°C overnight. Alkaline phosphatase-conju-
gated sheep anti-mouse immunoglobulin G (IgG)
(Promega) was used to detect immunocomplexes, which
were visualized using 5-bromo-4-chloro-3-indolylphos-
phate (BCIP)-nitroblue tetrazolium liquid substrate
(Sigma).
RNA extraction and gene array analysis
Following stimulation of A549 cells with 10 ng/ml TGF-
B1 for 15 mins, 30 mins, 2 hour and 4 hours, RNA isola-
tion, cDNA synthesis, in vitro transcription and microarray
analysis were performed as previously reported [31] and
in accordance with Affymetrix protocols(Affymetrix, Santa
Clara, California). Arrays were scanned with a confocal
scanner (Affymetrix). Each RNA sample derived from an
individual well and 15 min, 30 min, 2 hour and 4 hour in
vitro exposures were microarrayed in duplicate on HU133
Affymetrix chips. Image files were obtained through
Affymetrix GeneChip software (MAS5) and subsequently
robust multichip analysis (RMA) was performed. To
ensure the average was statistically significant a t-test and
p-value were generated. Only those genes with a p-value ≤
0.01 were included in subsequent bioinformatic analysis.
Expression data was further probed to identify those genes
whose expression is altered. Expression data for each time
point was compared to control and a signal log ratio of 0.6
or greater (equivalent to a fold change in expression of 1.5
or greater) was taken to identify significant differential
regulation. Using normalised RMA values, unsupervised
average linkage hierarchical cluster analysis was per-
formed using an Eisen software program [32]. Cluster
analysis is a group of mathematical techniques for the
identification of patterns in large datasets. Briefly, a dis-
tance metric is used to calculate the similarity between the
expression profiles of a group of genes. The more similar
the expression profiles of genes are, the closer they are
placed together on a dendrogram or tree. A list of 312
extracellular matrix proteins or modulators of matrix turn-
over was curated via the publicly available Onto-Compare
and Gene-Ontology databases [33].
Real-time PCR
Reverse transcription was carried out using the Promega
reverse transcription system. 1 µl of Oligo(dT)15 (0.5 µg/
µl) was mixed with 1 µg of total RNA and the volume
brought to 5 ml with sterile nuclease-free water. The mix-
ture was incubated at 70°C for 10 min and then placed on
ice. Once cooled the following was added for a 20 µl reac-
tion: 2 µl 10× transcription buffer, 0.5 µl RNasin (40
units/µl), 2 µl dNTP mix (10 mM), 4 µl MgCl2 (25 mM),
1  µl AVM-RT (Avian Myeloblastic Virus Reverse Tran-
scriptase)(20 units/µl), and brought to a final volume of
20 µl with nuclease free water. The sample was mixed by
repeated pipetting and then centrifuged to collect the sam-
ple at the bottom of the PCR reaction tube. The mixture
was incubated at 37°C for an hour and heated to 95°C forRespiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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2 min in order to inactivate the enzyme. The subsequent
cDNA was stored at 4°C until required.
Real time RT-PCR was performed on a TaqMan ABI 7700
Sequence Detection System® (AppliedBiosystems, Weiter-
stadt, Germany) using heat activated AmpliTaq Gold,
DNA polymerase (Amplitaq Gold, Applied Biosystems,
Weiterstadt, Germany) as previously described [34]. The
ribosomal 18S was used as an endogenous control for
normalisation of the target genes. Its primer and probe
were supplied as a PDAR (predeveloped assay reagent)
from Applied Biosystems with the probe labelled with VIC
at the 5' end. Primer and probes for the genes of interest
were designed in PrimerExpress® version 2.0(AppliedBio-
systems). The probes for the target genes were labelled
with fluorescent dye, FAM on the 5' end and the quencher
TAMRA onthe 3' end. PCR reactions were set up in sepa-
rate tubes with TaqMan Universal PCR Master Mix from
Applied Biosystems. Optimal concentration of primers
and probes were 200 nM for probe, 300 nM for its prim-
ers, and 100 nM reaction mix for PDARs. cDNA was
amplified on the 7700HT detection system (Applied bio-
science) at default thermal conditions: 2 min @50°C, 10
min @95°C for enzyme activation and the 40 cycles of 15
sec @95°C for denaturation and 1 min @60°C for
annealing and extension. Controls consisting of distilled
H2O were negative in all runs. All measurements were per-
formed in triplicate for each time point.
Following cycling, to ensure specificity, melt curve analy-
sis was carried out to verify the amplification of PCR prod-
ucts starting at 65°C and ramping to 90°C at .1°C/sec.
One peak in the melt curve indicated no secondary, non-
specific products were formed. All results were compared
to those for unstimulated A549 cells and analysed using
the delta delta Ct method. All experiments were per-
formed in triplicate for each time point.
Gene silencing by RNA interference
Knock down of gene expression was achieved using RNA
interference. Two siRNA duplexes were designed and syn-
thesised for silencing ADAM19 and ADAMTS9. (Qiagen
Inc. CA, USA). A chemically synthesized non-silencing
siRNA duplex that had no known homology with mam-
malian genes was used to control for non-specific silenc-
ing events. 2 × 105 A549 cells were added to each well of a
6-well plate in 3 ml growth media and incubated under
the standard conditions of 37°C and 5 % CO2 in a humid
incubator for 24 hr. A sufficient amount of growth
medium was added to 5 µg siRNA and 30 µl RNAifect
(Qiagen) to bring the final volume to 100 µl. Following
incubation, media was removed from the cells and this
mix was added drop-wise. 3 ml growth medium was
added and the cells were incubated for 48 hr under stand-
ard conditions. Following this, all growth media was
removed and cells were washed with sterile PBS. 1 ml TRI-
zol™ (Sigma) was added to each well and left for 10 min
at room temperature with occasional shaking. 200 µl
chloroform was added and the mixture was shaken, left at
room temperature for 15 min and centrifuged at 13,000 g
at 4°C for 15 min. The upper aqueous layer was trans-
ferred to a fresh 1.5 ml tube. 0.5 ml ice-cold isopropanol
was added to the aqueous phase, shaken and left to stand
on ice for 10 min before it was centrifuged at 13000 g at
4°C for 10 min. The supernatant was removed and 1 ml
of sterile 75 % ethanol was added to wash the pellet by
gentle vortexing and centrifugation at 7500 g for 5 min.
The ethanol was removed and the pellet was allowed to
air-dry for 5 min. Pellets were resuspended in 50 µl 0.1 %
DEPC treated H2O by heating at 60°C for 15 min. All
RNA was stored at -80°C.
Collagen Assay
Sircol collagen assay (Biocolour) was performed as per
manufacturer's guidelines. The dye reagent contains sirius
red in picric acid. Sirius Red is an anionic dye with sul-
phonic acid side chain groups. These groups react with the
side chain groups of the basic amino acids present in col-
lagen under specific conditions permitting determination
of mammalian collagens types I to V. Briefly 100 µl aliq-
uots of cell culture supernatant were incubated with the
dye reagent by gentle mixing for 30 mins at room temper-
ature. The dye-bound collagen was pelleted by centrifuga-
tion at 10000 g for 10 mins. Unbound dye was removed
by aspiration of the supernatant following centrifugation.
The collagen dye complex was washed with 500 µl etha-
nol to ensure complete removal of unbound dye. The col-
lagen bound dye pellet was recovered by solubilization in
an alkaline solution. Absorbance of bound collagen at
540 nm was determined using a spectrophotometer.
Bound collagen concentration was determined by com-
parison with absorbance standard curve of known con-
centration samples.
Results
Global changes in gene expression in response to TGF-β1
Exposure of A549 alveolar epithelial cells to 10 ng/ml
TGF-β1 was associated with significant changes in gene
expression. For all time points data was normalised using
RMA express and an average expression measure for each
time point used to identify alterations in gene expression.
RMA normalised data was found to be comparable across
the time series with the computed average expression
aligning to the individual chip hybridisation boxplots
(Figure 1, Panel A). Distinct temporal patterns of gene
expression were observed throughout the time course
exposure, with significant altered expression following 15
minutes exposure. The total number of genes altered was
lower following 30 minutes with a sustained increase seen
over the remaining time points. The same temporal pat-Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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Global changes in alveolar epithelial cell gene expression following exposure to 10 ng/ml TGF-β1 Figure 1
Global changes in alveolar epithelial cell gene expression following exposure to 10 ng/ml TGF-β1. Panel A shows 
a boxplot of normalised data and computed average arrays for each time point demonstrating comparability of the normalised 
data. Each array is performed in duplicate (A and B) and is shown beside their computed average (Ave). Arrays were per-
formed for control (Ctrl), and TGF-β1 stimulation at 15, 30,120, and 240 minutes. Panel B shows a summary of the observed 
alterations in gene expression at all the time points following TGF-β1 stimulation. Genes were defined as upregulated when 
signal log ratio (SLR) >0.6 and downregulated when SLR<-0.6.Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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tern of gene expression alterations was observed for both
up and down regulated transcripts. Of the 22,216 gene
sequences represented on the Affymetrix HGU133A oligo-
nucleotide microarray 2.9% (649) genes), 1.7% (383
genes), 2.89% (643 genes) and 6.01% (1339 genes) were
significantly altered following 15 minutes, 30 minutes, 2
hour and 4 hour exposure to TGF-β1 respectively (Figure
1, Panel B). Tables 1 and 2 highlight the genes whose
mRNA levels were most strikingly altered at 15, 30, 120
and 240 minutes post TGF-β1 exposure.
Baited Cluster analysis Identifies Extracellular Matrix 
Associated Genes as major responders to TGF-β1 exposure
Figure 2, panel A shows the result of unsupervised hierar-
chical cluster analysis of all alveolar epithelial cell genes
whose expression is significantly altered in response to
TGF-β1. As can be seen groups of genes are found to clus-
ter together depending on the kinetics of their altered
expression. Having delineated the global transcriptomic
response of alveolar epithelial cells to TGF-β1, we catego-
rized the significantly perturbed genes according to their
biological function. This approach permits rapid annota-
tion of large datasets for the identification of functional
patterns of dysregulation. All significantly perturbed
genes were used as input in classification searches. Figure
2 Panel B shows the overall pattern of regulation of key
functional families throughout the time course exposure.
All gene families studied were found to increase over time,
reflecting the increased transcriptomic activity in the latter
time points.
Table 1: Genes undergoing most striking up-regulation at 15, 30, 120 and 240 minutes post TGF-β1 exposure.
Accession Gene A549 Vs. 15 mins
NM_001554 Cysteine-rich, angiogenic inducer, 61 1.1
NM_006745 Sterol-C4-methyl oxidase-like 1.0
NM_004735 Leucine rich repeat interacting protein 1 0.9
AB023420 Heat shock 70KDa protein 4 0.8
NM_018063 Helicase, lymphoid-specific 0.8
NM_006621 S-adenosylhomocysteine hydrolase-like 1 0.8
NM_006364 Sec23 homolog A (S. cerevisiae) 0.7
Accession Gene A549 Vs. 30 mins
NM_003670 Basic helix-loop-helix domain containing, class 
B, 2
1.6
NM_002165 Inhibitor of DNA binding 1 1.6
NM_002229 Jun B proto-oncogene 1.6
NM_005655 TGFB inducible early growth factor 1.4
NM_001554 Cysteine-rich, angiogenic inducer, 61 1.2
NM_002228 v-jun sarcoma virus 17 oncogene homolog 1.2
NM_004907 Immediate early protein 1.1
Accession Gene A549 Vs. 120 mins
NM_000602 Serine proteinase inhibitor, clade E 3.0
S69738 Chemokine ligand 2 2.8
AL574210 Serine proteinase inhibitor, clade E 2.6
NM_002229 Jun B proto-oncogene 2.5
NM_004428 Ephrin-A1 2.3
NM_000641 Interleukin 11 2.2
NM_003897 Immediate early response 3 2.2
Accession Gene A549 Vs. 240 mins
NM_000602 Serine proteinase inhibitor, clade E 3.2
AL574210 Serine proteinase inhibitor, clade E 2.7
NM_001901 Connective tissue growth factor 2.7
S69738 Chemokine ligand 2 2.7
NM_000641 Interleukin 11 2.3
NM_003897 Immediate early response 3 2.0
NM_016109 Angiopoietin-like 4 1.9Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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Of the 312 ECM genes displayed on the microarray 95
were significantly altered in this setting. Figure 3 illus-
trates the extracellular matrix associated genes whose
expression was altered in response to TGF-β1 including
matrix proteins, such as members of the collagen family
and growth factors known to be involved in matrix regu-
lation, including connective tissue growth factor and
transforming growth factor. Figure 3, Panel A and B show
the expression patterns of up and downregulated tran-
scripts respectively.
TGF-β1 stimulation drives ADAM family gene expression in 
alveolar epithelial cells
Of note with respect to the mechanisms of fibrotic lung
injury was the finding of coordinate differential regula-
tion of ADAM gene family members. We focused on four
ADAM family members identified in the ECM cluster of
our oligonucleotide microarrays. ADAM19 and
ADAMTS9 were increased in response to TGF-β1 expo-
sure, whilst mRNA levels of ADAM28 and ADAMTS8 were
reduced.
Microarray findings were validated using quantitative real
time PCR. ADAM19 expression was significantly
enhanced by 6 fold at 4 hours (figure 4, panel A).
ADAMTS9 analysis showed an increase in response to
TGF-β1 exposure after 15 minutes and reaching a signifi-
cantly elevated level of 2 fold at 4 hours (figure 4, panel
B).
ADAMTS8 was identified as being downregulated in
response to TGF-β1. Real time quantitative PCR con-
firmed the TGF-β1 responsiveness of this gene in alveolar
epithelial cells at all but the 4 hour exposure time points,
Table 2: Genes undergoing most striking down-regulation at 15, 30, 120 and 240 minutes post TGF-β1 exposure.
Accession Gene A549 Vs. 15 mins
X7230 Corticotropin releasing hormone receptor -0.5
NM_014012 RAS-like GTP-binding -0.5
NM_018028 Hypothetical protein FLJ10211 -0.5
AW003030 Splicing factor 3b, subunit 1 -0.5
XM373433 Hypothetical protein BC002926 -0.5
NM_015638 Transient receptor potential cation channel -0.5
NM_020660 Connexin-36 -0.5
Accession Gene A549 Vs. 30 mins
NM_005469 Peroxisomal acyl-CoA thioesterase -0.5
AL571723 SPRY domain-containing SOCS box protein SSB-3 -0.5
N39314 Mitochondrial carrier triple repeat 1 -0.5
X02761 Fibronectin 1 -0.5
NM_022829 Solute carrier family 13 -0.5
AK026737 Fibronectin 1 -0.5
NM_020660 Connexin-36 -0.5
Accession Gene A549 Vs. 120 mins
AB012305 Cyclin-dependent kinase 2 -0.5
NM_001086 Arylacetamide deacetylase -0.5
NM_004083 Methionine-tRNA synthetase -0.5
NM_006933 Mitochondrial ribosomal protein S6 -0.5
NM_013453 Sperm protein associated with the nucleus, X-linked -0.5
NM_020660 Connexin-36 -0.5
AK026737 Fibronectin 1 -0.5
Accession Gene A549 Vs. 240 mins
NM_005345 Heat shock 70Kda protein 1A -0.5
NM_014158 Core 1 UDP-galactose -0.5
NM_005203 Collagen, type XIII, alpha 1 -0.5
L03203 Peripheral myelin protein 22 -0.5
NM_001417 Eukaryotic translation initiation factor 4B -0.5
NM_017960 Hypothetical protein FLJ20808 -0.5
AB012305 Cyclin-dependent kinase 2 -0.5Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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Functional classification of global gene expression changes in alveolar epithelial cells elicited by TGF-β1 Figure 2
Functional classification of global gene expression changes in alveolar epithelial cells elicited by TGF-β1. Panel A 
shows a cluster dendrogram of all arrays demonstrating aggregation of the data representative of each time point. Array image 
files were used as input to RMAExpress for normalization. In panel B all significantly dysregulated genes (SLR < -0.6 & SLR > 
0.6) were used to classify the TGF-β1 induced transcriptome in terms of biological function of the perturbed genes. Shown is a 
bar chart describing the percentage of dysregulated transcripts, from each family found to be significantly changed at each time 
point.Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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(Figure 4, Panel C). Downregulation of ADAM 28 mRNA
was confirmed by quantitative real-time PCR at 4 hours
(Figure 4, Panel D).
These data confirm the microarray-identified alterations
in ADAM family members in alveolar epithelial cells in
response to TGF-β1.
mRNA levels of ADAM Family members are altered in 
response to endogenous and exogenous stimuli
Having determined that exposure of alveolar epithelial
cells to TGF-β1 resulted in coordinate regulation of ADAM
family members we explored the effect of other fibrotic
stimuli on ADAM expression particularly IL-13 and IL-4.
Alveolar epithelial cells were exposed to 10 ng/ml IL-13
for 15, 30, 60, 120 and 240 mins and ADAM gene expres-
sion assessed by quantitative Real time PCR. Figure 5
Panel A and B demonstrates the induction of the TGF-β1
upregulated genes, ADAM19 and ADAMTS9 in response
to IL-13 stimulation. ADAM 19 was found to be signifi-
cantly induced at the 60 min time point post IL-13 expo-
sure, then the levels returning to almost baseline by 240
min. ADAMTS9 was significantly enhanced at all time
points, with maximal induction seen in the 240 min set-
ting. In contrast IL-13 was found to have little effect on the
TGF-β1 downregulated genes, ADAM28 and ADAMTS 8
(Figure 5, Panel C and D).
Interleukin 4 exposure had no significant effect on the
expression of ADAM 19 or ADAMTS9. There was a general
trend towards downregulation of these transcripts, the
opposite effects to that seen with TGF-β1. Suppression of
the TGF-β1 downregulated genes ADAM 28 and
A D A M T S 8  b y  I L - 4  w a s  i n t e r r o g a t e d  b y  r e a l  t i m e  P C R .
However only the latter time points of IL-4 exposure pro-
duced a statistically significant change in ADAM 28
expression (Figure 6, panel C).
Extracellular matrix family gene expression in response to TGF-β1 Figure 3
Extracellular matrix family gene expression in response to TGF-β1. A list of 312 extracellular matrix associated 
genes obtained from Onto-Compare was used to scan for genes undergoing significant perturbation in TGF-β1 stimulated cells. 
Panel A and B illustrate ECM genes whose expression was found to increase and decrease respectively. Arrays shown in this 
figure are control (Ctl), TGF-β1 stimulated time points 15 min (T15), 30 min (T30), 120 min (T120), and 240 min (T240).Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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EBV infection of A549 cells was confirmed by western blot
expression of latent membrane protein 1 (LMP1) in A549
infected cells (Figure 7). Having confirmed the viral infec-
tion of A549 cells with EBV we determined the effect of
this infection on ADAM gene expression. ADAM19 and
ADAMTS9 were found to be significantly induced in virus
infected alveolar epithelial cells. Stimulation of these
infected cells with TGF-β1 resulted in further enhanced
expression of these genes, suggesting a synergistic activity
of EBV and TGF-β1 in the fibrotic lung (Figure 8, panel A
and B). Of note was the finding that EBV infection had no
statistically significant effect on ADAM 28 gene expression
either alone or in conjunction with TGF-β1. Decreased
expression of ADAMTS8 was found in virus infected TGF-
β1 exposed alveolar epithelial cells (Figure 8, Panel C and
D).
ADAM 19 and ADAMTS9 Gene Silencing inhibits lung 
fibrosis in vitro
To determine the biological importance of enhanced
ADAM 19 and ADAMTS9 expression in response to TGF-
β1 exposure we evaluated the effect of gene knock down
on the cellular phenotype. To achieve this goal, specific
small interfering RNA oligonucleotide [35] probes were
designed and transfected into A549 alveolar epithelial
cells using the lipofectamine strategy as described. Follow-
ing transfection knockdown of the genes was confirmed
by quantitative PCR (Figure 9, Panel A). Transfected cells
were exposed to 10 ng/ml TGF-β1 for four hours as previ-
ously described and collagen (Types I-V) deposition, as a
hallmark of fibrosis, was determined using the Sircol
assay kit. Figure 9 panel B demonstrates reduced collagen
deposition in both ADAM 19 and ADAMTS9 siRNA trans-
ADAM mRNA expression levels in TGF-β1 stimulated alveolar epithelial cells Figure 4
ADAM mRNA expression levels in TGF-β1 stimulated alveolar epithelial cells. Confirmation of the oligonucleotide 
microarray identified ADAM 19, ADAMTS9, ADAMTS8 and ADAM 28 (Panels A, B, C and D respectively.) by quantitative real 
time PCR. All expression values were normalised to GAPDH to control for equivalence of loading. Data are quoted relative to 
control, which has a value of 1.Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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fected cells. These data suggest that the upregulation of
ADAM 19 and ADAMTS9 by TGF-β1 in the setting of lung
fibrosis plays a role in the deposition of collagen in the
cellular milieu, thereby contributing to extracellular
matrix deposition and lung scarring.
Discussion
To delineate the molecular events in the pathogenesis of
pulmonary fibrosis we utilised an oligonucleotide micro-
array strategy to identify alveolar epithelial genes and gene
clusters whose expression is altered in response to TGF-β1.
These studies identified a large number of genes whose
expression was altered in a temporal fashion. Functional
classification of the transcriptomic response identified
coordinate expression of important functional groups of
genes in response to TGF-β1. Particular focus was made
on genes that are associated with extracellular matrix and
it's remodelling. We curated the Affymetrix Human
Genome HU133a microarray to obtain a list of such genes
represented on the chip. Approximately 30% of this gene
cohort was found to be differentially regulated further
underpinning the relative contribution of matrix mole-
cules and mediators to the response to TGF-β1. Represent-
ative among these extracellular matrix genes were growth
factors, collagens and members of the ADAM gene family.
The interaction of epithelial cells with other local and
infiltrating cell types drives the further articulation of the
fibrotic response in the lung. The ability of ADAM family
members to regulate the interaction of these cell types and
indeed to regulate their interaction with the extracellular
matrix raises the hypothesis that these mediators are
important in driving the local fibrotic milieu in the lung.
The ADAM gene family encompasses the ADAM (A disin-
tegrin and metalloproteinase domain containing protein)
and ADAMTS (A disintegrin-like and metalloproteinase
with thrombospondin type I motif) proteins. The
ADAMTSs are soluble proteins that can bind to the ECM
ADAM mRNA expression in response to interleukin-13 Figure 5
ADAM mRNA expression in response to interleukin-13. A549 alveolar epithelial cells were exposed to 10 ng/ml Inter-
leukin 13; mRNA expression of ADAM 19 (Panel A), ADAM 28 (Panel B), ADAMTS9 (Panel C) and ADAMTS8 (Panel D) quan-
tified by Real Time PCR is shown. All expression values were normalised to GAPDH to control for equivalence of loading. 
Data are quoted relative to control, which has a value of 1.Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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through the TS motifs. To date 34 members of the ADAMs
family have been described, of which approximately 50%
have been demonstrated to have protease activity. The
substrates of ADAM protease activity are either integral
membrane proteins or extracellular matrix proteins. In
addition to their proteolytic activity, a number of ADAMs
have been shown to bind integrins, via their disintegrin
domain [36]. This dual activity of ADAMs suggests that
these molecules are key mediators of biological processes
such as cell-cell adhesion, ectodomain shedding, myob-
last fusion and development. In the context of lung dis-
ease, this family is noteworthy. The possible role for
ADAM family genes in lung fibrosis has been intimated by
the observation that ADAM 10 autoantibody is associated
with dermatomyositis related lung fibrosis and was
shown to be present in one patient with IPF [37].
ADAM33 polymorphisms have also been shown to play a
role in the development of asthma and also in disease
progression via effects on airway remodelling [38].
The ADAM gene family is characterised by members that
possess both proteolytic and cell-cell and cell-matrix inter-
action promoting activities. Thus the matrix proteolytic
activities of ADAMs may represent an important facet of
the development of pulmonary fibrosis, as their differen-
tial expression may alter the balance of matrix turnover.
ADAM genes identified in this study have previously been
associated with ventricular septal defects and valvular
defects (ADAM19) [39], fibrotic eye disease (ADAMTS9)
[40], disrupting angiogenesis (ADAMTS8) [41], and cell
adhesion (ADAM 28) [42]. Functional assessment of the
role of these genes in the setting of the lung was described
using a gene knock down based strategy. These investiga-
tions showed an effect on collagen deposition in cells
ADAM mRNA expression in response to interleukin-4 Figure 6
ADAM mRNA expression in response to interleukin-4. A549 alveolar epithelial cells were exposed to 10 ng/ml Inter-
leukin 4. Shown are mRNA expressions of ADAM 19 (Panel A), ADAM 28 (Panel B), ADAMTS9 (Panel C) and ADAMTS8 
(Panel D) quantified by Real Time PCR. All expression values were normalised to GAPDH to control for equivalence of load-
ing. All measurements were completed in triplicate. Data are quoted relative to control, which has a value of 1.Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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where the ADAM gene was knocked down, thus illustrat-
ing the importance of dysregulation of this gene family in
the setting of lung fibrosis.
Having demonstrated the responsiveness and functional
activity of ADAM family members in response to TGF-β1
we explored their induction in response to other endog-
enous and exogenous pro-fibrotic insults. We determined
the effect of IL-4 and IL-13 on alveolar epithelial cell
ADAM production. Whilst the specific dysregulation of
ADAM family members by these cytokines was different
to that elicited by TGF-β1, the general trend of ADAM
response remained the same. These data suggest that the
ADAM family response may be more indicative of the
overall fibrotic activity rather than being a stimulus spe-
cific effect. These findings lend further weight to the argu-
ADAM mRNA expression levels in Epstein Barr Virus infected alveolar epithelial cells Figure 8
ADAM mRNA expression levels in Epstein Barr Virus infected alveolar epithelial cells. Using real time PCR the 
effect of EBV infection and TGF-β1 costimulation on ADAM expression was determined. ADAM expression in A549 cells (C), 
A549 cells stimulated with TGF-β1 (TGF), EBV infected A549 cells with (VTGF) and without (V) TGF-β1 are shown. Expres-
sion levels of ADAM 19 (Panel A), ADAM 28 (Panel B), ADAMTS9 (Panel C) and ADAMTS8 (Panel D) are shown. All expres-
sion values were normalised to 18S rRNA to control for equivalence of loading. All measurements were completed in 
triplicate. Data are quoted relative to control, which has a value of 1.
Epstein Barr Virus infection of alveolar epithelial cells Figure 7
Epstein Barr Virus infection of alveolar epithelial 
cells. EBV infection of A549 alveolar epithelial cells was con-
firmed by western blotting for the viral protein LMP1. LMP1 
was detected in Akata cells (Control) as a positive control. 
Lanes V1 and V2 demonstrate LMP-1 protein expression in 
infected A549 alveolar epithelial cells. Each lane represents 
protein taken from separate experiments containing 4 × 105 
cells.Respiratory Research 2006, 7:114 http://respiratory-research.com/content/7/1/114
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ment that ADAM genes are central in mediating fibrosis as
opposed to being an artefact of the experimental model.
Of particular note was the finding that viral infection itself
resulted in ADAM family dysregulation in these cells, an
effect that was further enhanced in experiments where
repeated injury consisting of both EBV infection and TGF-
β1 exposure induced ADAM gene expression. Whilst the
ADAM gene expression was not as great in EBV infected
cells as it was in A549 cells stimulated with TGF-β1, a sig-
nificant rise in ADAM19 and ADAMTS9 expression was
observed. The combined stimulation of A549 cells with
both EBV and TGF-β1 resulted in an additional increase in
ADAM19 and ADAMTS9 expression.
These data strengthen the hypothesis that the initiation
and progression of lung fibrosis is due to injury of the epi-
thelial cell with abnormal healing. Repetitive injury due
to EBV infection is one plausible mediator for the devel-
opment of fibrosis. It is of note that the ADAM response
was consistently observed following different experimen-
tal exposures, underpinning the fact that these observed
changes in ADAM expression and functionality may be of
clinical importance and are not merely representative of
experimental and model derived artefacts.
The data highlight the complex mechanism underpinning
the initiation and progression of IPF and underline mech-
anisms for both the multifactorial nature of disease initi-
ation and the mediators of deposition of extracellular
matrix.
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